Table 1 Baseline outcome and covariate levels for adult and children analysis samples, by intervention groups
From: Health impacts of a randomized biomass cookstove intervention in northern Ghana
Variable | Full Sample | Gyapa/ Gyapa | Philips/ Philips | Gyapa/ Philips | Control | |
|---|---|---|---|---|---|---|
ADULT WOMEN | Sample Size | 184 | 42 | 48 | 47 | 47 |
Age (yrs) Mean (Range) | 37.2 (18.4,82.6) | 40.0 (19.6,82.6) | 34.5 (18.7,56.6) | 37.7 (18.6,68.6) | 36.8 (18.4,73.6) | |
Smoker in house (%) | 33.1% | 44.4% | 35.7% | 27.9% | 26.2% | |
Respiratory symptoms | 43.5% | 40.5% | 43.8% | 48.9% | 40.4% | |
Headache | 67.8% | 65.9% | 72.9% | 78.7% | 53.2% | |
Eye irritation | 31.0% | 31.0% | 20.8% | 40.4% | 31.9% | |
Burns | 21.2% | 14.3% | 20.8% | 25.5% | 23.4% | |
CRP (ng/ml) | 42.0 (64.6) | 24.8 (31.1) | 50.9 (68.9) | 43.3 (63.5) | 47.1 (80.4) | |
Serum Amyloid A (ng/ml) | 146.7 (720.0) | 70.2 (126.5) | 282.6 (1352.5) | 114.6 (235.5) | 108.2 (310.3) | |
Sicam (ng/ml) | 12.2 (6.5) | 11.1 (4.1) | 12.9 (6.4) | 13.0 (7.7) | 11.9 (7.0) | |
sVCAM (ng/ml) | 19.5 (8.0) | 19.9 (9.5) | 19.4 (7.3) | 19.5 (8.0) | 19.2 (7.6) | |
IL-1β (pg/ml) | 0.7 (0.9) | 0.90 (1.34) | 0.72 (0.75) | 0.59 (0.48) | 0.71 (0.89) | |
IL-6 (pg/ml) | 0.09 (0.05) | 0.08 (0.03) | 0.11 (0.08) | 0.09 (0.03) | 0.08 (0.04) | |
IL-8 (pg/ml) | 7.7 (4.0) | 7.5 (2.7) | 8.02 (5.0) | 7.7 (4.2) | 7.4 (3.7) | |
TNF-a (pg/ml) | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) | |
CHILDREN – SELF-REPORTED HEALTH & BIOMARKERS | Sample Size | 211 | 50 | 49 | 53 | 59 |
Age (yrs) Mean (Range) | 3.1 (0.8,5.2) | 3.0 (1.1,5.2) | 3.1 (1.0,5.0) | 3.3 (1.2,5.1) | 3.1 (0.8,5.1) | |
Female (%) | 49.3% | 52.0% | 53.1% | 41.5% | 50.9% | |
Respiratory symptoms | 50.2% | 48.0% | 51.0% | 50.9% | 50.9% | |
CRP (ng/ml) | 135.9 (294.9) | 55.7 (93.3) | 172.1 (308.9) | 87.6 (179.0) | 227.2 (428.8) | |
Serum Amyloid A (ng/ml) | 406.6 (1406.6) | 98.1 (152.8) | 354.5 (850.8) | 165.0 (295.1) | 928.2 (2460.1) | |
sICAM (ng/ml) | 19.4 (7.3) | 18.4 (6.1) | 19.6 (9.5) | 19.9 (7.1) | 19.7 (6.2) | |
sVCAM (ng/ml) | 28.0 (11.3) | 26.9 (10.6) | 25.8 (8.8) | 27.5 (12.6) | 31.3 (12.2) | |
IL-1B (pg/ml) | 0.34 (0.24) | 0.31 (0.21) | 0.34 (0.24) | 0.34 (0.22) | 0.35 (0.29) | |
IL-6 (pg/ml) | 0.14 (0.18) | 0.11 (0.05) | 0.14 (0.18) | 0.14 (0.20) | 0.17 (0.23) | |
IL-8 (pg/ml) | 10.8 (10.1) | 9.8 (6.3) | 9.8 (9.5) | 9.9 (6.7) | 13.4 (14.7) | |
TNF-a (pg/ml) | 0.43 (0.32) | 0.42 (0.16) | 0.41 (0.21) | 0.46 (0.55) | 0.43 (0.21) | |
CHILDREN - ANTHRO | Sample Size | 184 | 49 | 40 | 43 | 52 |
Age in yrs. Mean (Range) | 3.1 (0.8, 5.2) | 3.0 (1.1, 5.2) | 3.0 (1.0, 5.0) | 3.2 (1.3, 5.1) | 3.2 (0.8, 5.1) | |
Female (%) | 49.5% | 54.2% | 53.7% | 39.1% | 51.0% | |
HAZ | −1.46 (1.53) | −1.26 (1.68) | −1.58 (1.16) | −1.37 (0.89) | −1.62 (1.98) | |
WAZ | −0.98 (1.34) | −1.00 (1.23) | −0.82 (1.14) | −0.83 (0.97) | − 1.18 (1.76) | |
MUACZ | −0.54 (0.97) | −0.48 (1.01) | − 0.56 (1.00) | − 0.49 (0.87) | −0.64 (1.01) |